Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy

Rania Refaat, Eshraq Arabi Mohamed Ammar, Mohammad Abd Alkhalik Basha, Ahmed Mohamed Abouelhoda, Pasant M Abo-Elhoda, Mohamed Mohsen Tolba Fawzi, Mohamed MohsenTolba Fawzi, Abd El-Aziz Galal El-Dein El-Darwish, Khaled M Abdallah, Ahmed Abdelrady Ahmed
European journal of radiology · 2026 · vol. 196 , pp. 112712 · doi:10.1016/j.ejrad.2026.112712 · PMID:41628502 · W7126114068
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This trial found that uterine artery embolization was more effective than dienogest at resolving pain and bleeding symptoms and reducing adenomyosis lesion size at six months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

RATIONALE AND OBJECTIVES: Adenomyosis significantly impairs quality of life, yet optimal uterine-sparing management remains uncertain. While both uterine artery embolization (UAE) and dienogest show promise, no direct comparison exists. This study compared their 6-month efficacy in treating symptomatic adenomyosis. PATIENTS AND METHODS: This prospective, single-center, randomized controlled trial enrolled 60 patients with MRI-confirmed adenomyosis desiring uterine preservation between January and July 2025, randomly assigned (1:1) to UAE (n = 30) or 2 mg/day dienogest (n = 30). Co-primary outcomes were complete resolution of chronic pelvic pain and heavy menstrual bleeding at 6 months. Secondary outcomes included visual analog scale (VAS) dysmenorrhea scores, Uterine Fibroid Symptom and Quality of Life (UFS-QoL) symptom severity and health-related quality of life (HRQOL) scores, hemoglobin levels, junctional zone thickness, and uterine volume measured at baseline, 3 months, and 6 months. RESULTS: UAE achieved higher complete resolution rates for chronic pelvic pain (93.3% vs. 66.7%; p = 0.010; relative risk [RR] = 1.40) and heavy menstrual bleeding (90.0% vs. 56.7%; p = 0.004; RR = 1.59), with composite success in 86.7% versus 50.0% (RR = 1.73; number needed to treat = 3). At 6 months, UAE was associated with significantly better outcomes for VAS dysmenorrhea (1.27 ± 1.23 vs. 2.10 ± 1.25; p = 0.016), symptom severity scores (31.48 ± 9.78 vs. 45.36 ± 9.55; p < 0.001), HRQOL scores (66.25 ± 7.35 vs. 50.82 ± 10.11; p < 0.001), hemoglobin levels (10.55 ± 1.49 vs. 10.19 ± 1.55 g/dL; p = 0.010), junctional zone reduction (33.5% vs. 14.0%; p = 0.005), and uterine volume reduction (17.6% vs. 7.3%; p = 0.006). CONCLUSION: At 6 months, UAE achieved better symptom relief and anatomical outcomes than dienogest, supporting UAE as an effective uterine-sparing therapy for symptomatic adenomyosis.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

adenomyosischronic_pelvic_paindysmenorrhea

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-11T06:15:22.776949+00:00
License: CC0 · commercial use OK